Teva Pharmaceutical Industries (NYSE:TEVA) Updates FY 2026 Earnings Guidance

Teva Pharmaceutical Industries (NYSE:TEVA) updated its FY 2026 earnings guidance on Wednesday morning. The company provided EPS guidance of 1.910-2.110 for the period, compared to the consensus earnings per share estimate of 2.170. The company issued revenue guidance of $16.5 billion-$16.9 billion, compared to the consensus revenue estimate of $16.7 billion.

Analyst Ratings Changes

TEVA has been the subject of a number of analyst reports. Bank of America increased their price objective on shares of Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the stock a “buy” rating in a research note on Thursday, April 9th. Piper Sandler lifted their target price on shares of Teva Pharmaceutical Industries from $42.00 to $44.00 and gave the company an “overweight” rating in a research note on Tuesday. Truist Financial upped their target price on shares of Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the stock a “buy” rating in a report on Thursday, April 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research note on Friday, July 17th. Finally, Wall Street Zen cut Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. Nine equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $42.00.

Teva Pharmaceutical Industries Price Performance

TEVA stock traded up $2.24 during mid-day trading on Wednesday, hitting $33.91. The company had a trading volume of 10,688,561 shares, compared to its average volume of 7,263,081. The company has a 50-day moving average price of $33.19 and a 200 day moving average price of $32.68. Teva Pharmaceutical Industries has a 12-month low of $14.99 and a 12-month high of $37.35. The company has a market capitalization of $38.99 billion, a price-to-earnings ratio of 25.52, a P/E/G ratio of 3.28 and a beta of 0.86. The company has a quick ratio of 0.78, a current ratio of 1.01 and a debt-to-equity ratio of 1.70.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings data on Wednesday, July 29th. The company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.08 by ($0.06). Teva Pharmaceutical Industries had a net margin of 9.01% and a return on equity of 43.53%. The firm had revenue of $4.14 billion for the quarter, compared to analysts’ expectations of $4.02 billion. During the same quarter in the previous year, the business earned $0.66 EPS. The company’s revenue for the quarter was down .8% on a year-over-year basis. Teva Pharmaceutical Industries has set its FY 2026 guidance at 1.910-2.110 EPS. On average, research analysts anticipate that Teva Pharmaceutical Industries will post 1.99 earnings per share for the current year.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, EVP Christine Fox sold 21,258 shares of the firm’s stock in a transaction that occurred on Thursday, April 30th. The stock was sold at an average price of $35.31, for a total transaction of $750,619.98. Following the completion of the transaction, the executive vice president owned 63,647 shares in the company, valued at $2,247,375.57. This trade represents a 25.04% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Richard Daniell sold 30,000 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Tuesday, May 5th. The stock was sold at an average price of $35.40, for a total value of $1,062,000.00. Following the completion of the sale, the executive vice president directly owned 55,755 shares in the company, valued at approximately $1,973,727. The trade was a 34.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 465,931 shares of company stock worth $16,332,989 over the last three months. 0.54% of the stock is owned by company insiders.

Trending Headlines about Teva Pharmaceutical Industries

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Innovative brands delivered strong growth. Teva reported second-quarter revenue of approximately $4.1 billion, ahead of the $4.02 billion consensus estimate. Its three key innovative brands grew 43% year over year in local-currency terms to more than $1 billion, supporting the company’s strategy of shifting its portfolio toward higher-growth products. Teva Delivers Strong Q2 Results and Raises Outlook
• Positive Sentiment: UZEDY momentum prompted a higher outlook. UZEDY U.S. sales rose 43% year over year to a record $77 million in the quarter. Teva raised its 2026 UZEDY revenue forecast to $270 million–$290 million from $250 million–$280 million, reinforcing expectations for growth from long-acting injectable treatments. UZEDY Record Q2 Net Sales and Outlook
• Positive Sentiment: Trading activity and analyst sentiment were supportive. Call-option volume was about 136% above its average daily level, indicating increased bullish speculation. Piper Sandler also raised its price target to $44 and maintained an overweight rating. The company’s broader branded-drug pipeline has further attracted investor attention.
• Neutral Sentiment: Teva raised its 2026 revenue guidance to $16.5 billion–$16.9 billion, broadly in line with the $16.7 billion consensus. The company also raised outlooks for its three key innovative brands.
• Negative Sentiment: Profitability and generics remained concerns. Quarterly EPS of $0.02 missed the $0.08 consensus, while revenue declined about 1% year over year, mainly because of lower generics sales. Full-year EPS guidance of $1.91–$2.11 is below the $2.17 analyst consensus, limiting the upside from the revenue outlook. Teva Second-Quarter Earnings Report

Institutional Investors Weigh In On Teva Pharmaceutical Industries

A number of hedge funds have recently bought and sold shares of the business. Aster Capital Management DIFC Ltd bought a new position in Teva Pharmaceutical Industries during the 4th quarter valued at about $25,000. Caitong International Asset Management Co. Ltd boosted its position in shares of Teva Pharmaceutical Industries by 567.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,334 shares of the company’s stock valued at $42,000 after buying an additional 1,134 shares during the period. Global Retirement Partners LLC boosted its position in shares of Teva Pharmaceutical Industries by 27.3% during the fourth quarter. Global Retirement Partners LLC now owns 1,360 shares of the company’s stock valued at $42,000 after buying an additional 292 shares during the period. Advocate Investing Services LLC bought a new position in shares of Teva Pharmaceutical Industries during the fourth quarter valued at approximately $53,000. Finally, DV Equities LLC bought a new position in shares of Teva Pharmaceutical Industries during the fourth quarter valued at approximately $69,000. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.